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Alzheimer disease (AD), the most common neuro-
degenera  tive disorder, is characterized by the accumu-
lation of amyloid beta (Aβ) and tau into plaques and 
tangles, respectively. Other neurodegenerative disorders 
such as Parkinson disease (PD) and dementia with Lewy 
bodies (DLB) are broadly characterized as synucleino-
pathies because of the accumulation of alpha-synuclein 
(SNCA) into Lewy bodies. Although these disorders are 
not the same, there is overlap with respect to the patho-
genic proteins Aβ, SNCA, and tau. A large subset of 
patients with AD (Lewy body variant, AD-LBV) exhibit 
Lewy body pathology in addition to plaques and tangles 
[1]. Lewy body pathology is also common in patients 
with early-onset familial AD [2,3]. Conversely, dementia 
in PD (PDD) may involve AD-related pathological 
changes. Increased Aβ plaque burden and low cerebro-
spinal ﬂ  uid (CSF) Aβ levels have been demonstrated in 
PDD and are highly correlated with increased Lewy body 
pathology [4-7]. Evidence linking tau pathology to PDD is 
less evident, although one study has demonstrated 
increased phospho-tau in post-mortem PDD brain [8]. 
Recent evidence suggests that this pathological overlap 
may predict the clinical course of the disease. Patients 
with AD-LBV exhibit a more aggressive disease course, a 
more severe memory impairment, and a more rapid rate 
of cognitive decline compared with AD patients without 
Lewy body pathology [9]. Reductions in CSF Aβ levels 
have been reported in PDD subjects and are associated 
with memory impairment [6], and there is a strong 
association between declines in CSF Aβ and longitudinal 
declines in cognition over time in patients with PDD [10]. 
Low CSF Aβ levels are considered a reﬂ  ection of increased 
Aβ deposition in brain [11] and, along with high CSF tau 
levels, act as a biomarker to predict the presence of AD 
neuropathology [12] and a more rapid rate of cognitive 
decline during the course of the disease [13,14]. Th  us, 
although there does not appear to be an association 
between CSF tau, PDD, and cognitive decline, at least one 
AD biomarker, CSF Aβ, reﬂ  ects cognitive impairment in 
PD. From a clinical perspective, these studies are impor-
tant because they link PD, a classic SNCA-asso  ciated 
disease, with AD, suggesting interplay between some of 
the pathophysiological mechanisms underlying these 
diseases.
Th  e human clinical studies discussed above suggest 
that, in the etiology of these diseases, there may be a 
common thread involving the synergistic interaction of 
the pathogenic proteins Aβ, SNCA, and tau. However, 
understanding the mechanism of a disease process in 
humans is inherently diﬃ     cult through clinical studies. 
Th  us, animal models are needed to provide an experi-
mentally accessible system in which to study the 
molecular pathogenesis of a disease. To this end, an 
important recent study by Clinton and colleagues [15] 
describes a mouse model that exhibits the combined 
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© 2010 BioMed Central Ltdpathologies of Aβ, tau, and SNCA. Th  is animal was 
generated by introducing a mutant human SNCA trans-
gene (SNCAA53T) into the 3xTg-AD triple-transgenic 
mouse (hAPPSW/hTauP301L/hPS1M146V). Th   e authors report 
that the resulting 4xTg mice exhibit increased insoluble 
Aβ and thioﬂ   avin-S-positive plaque pathology and 
increased insoluble tau and AT8 phosphorylated tau 
immunoreactivity compared with the 3xTg-AD mouse 
model, suggesting that the addition of SNCA promotes 
the accumulation of these pathogenic proteins. Addition-
ally, the 4xTg mice exhibit increased insoluble SNCA, 
increased phosphorylated SNCA, and accelerated depo-
si  tion of Lewy body inclusions compared with single-
transgenic SNCA mice, suggesting an eﬀ  ect of Aβ and 
tau on SNCA pathology. Importantly, the 4xTg mice 
exhibit accelerated cognitive decline compared with 
3xTg-AD mice and single-transgenic SNCA mice, 
suggesting that the exacerbated pathology is clinically 
relevant. Th   e authors conclude that Aβ, tau, and SNCA 
can synergistically promote the aggregation and depo  si-
tion of each other and thereby accelerate cognitive 
decline.
Th  ere are many animal models of neurodegenerative 
diseases, yet none fully reproduces the full neuro-
pathological or clinical features of the human disease. 
Th  e mouse model described above is unique because it 
exhibits all three proteinopathies clinically associated 
with AD, DLB, and PD. But what disease does this animal 
model represent? One might argue that it represents a 
composite of several distinct diseases – AD, DLB, PD, 
and tauopathies – that do not naturally occur together. 
Th   e resulting pathologies may be driven separately by the 
diﬀ   erent transgenes: plaque pathology by the AD-
associated APP and PS1 mutations; tau pathology by the 
frontotemporal dementia with Parkinsonism-chromo-
some 17 (FTDP-17) mutation in tau; and Lewy body 
pathology by the familial PD-associated mutation in 
SNCA. However, this mouse model strongly suggests 
that an interaction among these proteins results in a 
behavioral manifestation that models the clinical 
characteristics of these diseases to some extent. 
Importantly, clinical research in humans indicates that 
these diseases may be linked by common patho  logical 
changes involving these proteins and that these changes 
have clear clinical eﬀ  ects.
Th  e molecular mechanisms that promote the syner-
gistic aggregation of Aβ, tau, and SNCA remain to be 
elucidated. Th  ese proteins, and their aggregated patho-
logical forms, often do not reside in the same neurons or 
cellular compartments, making physical inter  actions 
problematic. Th  us, one can hypothesize that there may 
be a common underlying pathogenic mechanism that 
independently promotes the aggregation of multiple 
proteins in susceptible cells. However, the data from 
Clinton and colleagues suggest a more direct cooperative 
interaction in which the aggregating proteins themselves 
may seed each other. Under pathological conditions, 
there may be aberrant co-localization of these proteins, 
as either oligomers or ﬁ  brils. Th   ese proteins may then act 
as seeds to promote the ﬁ  brillization of one another in a 
synergistic manner. Th  e amyloidogenic nature of these 
proteins may play a role in this interaction. Such a 
seeding mechanism has been proposed to explain how 
tau and SNCA inclusions can co-localize in the same cells 
in several neurodegenerative diseases, including AD and 
DLB [16]. Th  e authors propose a mechanism by which 
amyloidogenic SNCA forms a seed that then primes tau 
to acquire a conformational change allowing its poly-
meri  zation. In support of this seeding mechanism is a 
ﬁ  nding by Yagi and colleagues [17] that the amyloid ﬁ  bril 
formation of SNCA is enhanced by the preformed 
amyloid seeds of other proteins. Additional support 
comes from data demonstrating the co-localization of 
epitopes of tau and SNCA in Lewy bodies in some 
neurons [18] as well as the co-localization of Aβ and tau 
in neuroﬁ  brillary tangles and extracellular Aβ deposits 
(reviewed in [19]). Of particular clinical relevance is that 
interfering with this seeding process could impact the 
aggregation of multiple pathogenic proteins and, hope-
fully, impact the clinical progression of disease.
In summary, the study by Clinton and colleagues is a 
good example of how animal models studied in parallel 
with their human diseases can be complementary and 
provide novel information about the mechanisms of the 
disease process. In addition, such a model may provide 
opportunities for screening therapeutic interventions 
and validating diagnostic tests that could be useful for a 
number of closely related neurodegenerative diseases.
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